Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma.

ABSTRACT:

Lessons learned

Accrual to cervical cancer studies remains a puzzling challenge given the lack of options and the dismal prognosis of this disease. The majority of patients referred for a trial such as this have very advanced disease that is difficult to manage.The observation of 4 partial responses among the 41 patients indicates that ixabepilone has some activity but not sufficient for further development without greater understanding of mechanisms of sensitivity and resistance.

Background

Ixabepilone is a microtubule-stabilizing agent approved for metastatic breast cancer. Preclinical data have shown that ixabepilone is active in taxane-sensitive and -resistant cells. Metastatic cervical carcinoma (mCC) has a poor prognosis and no established second-line therapies. This s

SUBMITTER: Burotto M 

PROVIDER: S-EPMC4492237 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature